Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co P/B

The P/B (Price-to-Book Ratio) of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 25, 2026 is 1.58. In the previous year, P/B (Price-to-Book Ratio) was 1.68 — a change of -5.95% (lower).

P/B

1.58

YoY

-5.95%

Last updated:

P/B (Price-to-Book Ratio) of Harbin Pharmaceutical Group Co is 2025 1.58 . P/B (Price-to-Book Ratio) of Harbin Pharmaceutical Group Co was 2024 1.68 . It decreases by -5.95% lower compared to the previous year.

The Harbin Pharmaceutical Group Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
1.53 CNY
Jan 1, 2019
1.65 CNY
Jan 1, 2020
2.58 CNY
Jan 1, 2021
2.34 CNY
Jan 1, 2022
2.08 CNY
Jan 1, 2023
1.90 CNY
Jan 1, 2024
1.68 CNY
Jan 1, 2025
1.58 CNY
The Harbin Pharmaceutical Group Co P/B history
YEARP/BYoY
1.58-5.95%
1.68-11.70%
1.90-8.32%
2.08-11.17%
2.34-9.55%
2.58+56.81%
1.65+7.49%
1.53+20.22%
1.28+11.36%
1.14-10.18%
1.27+16.81%
1.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

P/B (Price-to-Book Ratio) of Harbin Pharmaceutical Group Co is 1.58 in 2025.

P/B (Price-to-Book Ratio) of Harbin Pharmaceutical Group Co changed from 1.68 to 1.58, representing a -5.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Harbin Pharmaceutical Group Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Harbin Pharmaceutical Group Co